Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02467946 | Hodgkin Lymphoma Treatment With Adcetris and Levact in the Old Patient | PHASE1 | COMPLETED | 60 | — | — | Jan 14, 2016 | Apr 6, 2022 | Jan 4, 2023 | 1 | France |
To evaluate the tolerability and toxicity of Adcetris-Levact (BV-Be) association.
To evaluate the efficacy in terms of Response Rate after treatment completion of Adcetris-Levact (BV-Be) association.
| Arm | Type | Description |
|---|---|---|
| Adcetris-Levact (BV-Be) Association | EXPERIMENTAL | Adcetris® (BV) : 1.2 mg/kg intravenously every 3 weeks Levact® (Be): 90 mg/m2/day intravenously for 2 days every 3 weeks. Up to 6 cycles |
| Name | Type | Description |
|---|---|---|
| Adcetris-Levact | DRUG | Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles. |
Inclusion Criteria: 1. Patients with advanced classical Hodgkin Lymphoma according to the World Health Organization classification. All Hasenclever IPS prognostic groups accepted 2. Stages IIB to IV B 3. Age 60-80 years included 4. Patient not previously treated 5. ECOG ≤ 2 6. Patient with adequate...